Clinical Trials Logo

Filter by:
NCT ID: NCT01609075 Completed - Colorectal Cancer Clinical Trials

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer in Italy (BEWARE)

Start date: June 2012
Phase: N/A
Study type: Observational

This observational, multicenter, retrospective/prospective study will evaluate the use of Avastin (bevacizumab) in clinical practice in patients with metastatic colorectal cancer. Patients having initiated first-line treatment with a fluoropyrimidine-based chemotherapy and Avastin will be followed for up to 15 months.

NCT ID: NCT01608932 Completed - Clinical trials for Multiple Chronic Diseases Among Diabetes Mellitus, Chronic Obstructive Pulmonary Diseases and Heart Failure

Life-long Monitoring of Frail Patients With Chronic Diseases

Start date: April 2012
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate whether telemonitoring of frail patients with chronic diseases produces benefits in terms of reduced readmissions, improved health related quality of life, and improved health status. In addition, the trial evaluates the economic and organisational impact of the telemonitoring service and examines its acceptability by patients and health professionals.

NCT ID: NCT01608789 Completed - Clinical trials for Stress Urinary Incontinence

Virtue® European Study

Start date: August 27, 2012
Phase: N/A
Study type: Interventional

This study is a prospective, single arm, non-randomized, multi-center clinical study that will be conducted in Europe. It is designed to assess efficacy and safety of the Virtue® Male Sling in post-prostatectomy urinary incontinence.

NCT ID: NCT01608555 Completed - Cystic Fibrosis Clinical Trials

Tobramycin 300 mg Once-a-day (o.d.) Aerosol in Adults With Cystic Fibrosis

Start date: January 2012
Phase: Phase 4
Study type: Interventional

The study will include 10 adult patients with cystic fibrosis. The aim of the study is to evaluate whether Tobramycin 300 mg aerosol once-a-day for 28 days can reduce the bacterial load in the airways. Secondary end-point is the evaluation of variation in bacterial susceptibility during and at the end of study period.

NCT ID: NCT01607957 Completed - Colorectal Cancer Clinical Trials

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

RECOURSE
Start date: June 17, 2012
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the efficacy and safety of TAS-102 versus placebo in patients with refractory metastatic colorectal cancer.

NCT ID: NCT01606683 Completed - Clinical trials for Formula Feeding of Healthy Full Term Infants

Impact of Infant Feeding on Newborn Metabolomic Profile

Start date: April 2012
Phase: N/A
Study type: Interventional

The purpose of this study is the evaluation with untargeted modalities, of the urine metabolomic profile in a group of infants fed with a standard formula, a group of infants fed with a formula supplemented with functional ingredients and a group of breast-fed infants.

NCT ID: NCT01606449 Completed - Clinical trials for Paraesophageal Hernia

Follow-up of Patients Operated Upon for Type II-IV Hiatal Hernia

Start date: January 1980
Phase: N/A
Study type: Observational

Surgical therapy for gastroesophageal reflux disease (GERD) and hiatal hernia (HH) can achieve outcomes that afford the patient lifelong satisfaction. The published results obtained with this surgery may not be considered to be definitive in relation to the length of follow-up or patients' life expectancy. The real recurrence rates and the results of surgery for GERD are difficult to assess due to the lack of serial time points during the follow-up. Further bias may have been introduced into the analysis by a lack of appropriate controls. The results of surgical therapy for type II-IV HH are even more controversial because of the high rate of anatomical relapse and the different methods of follow-up adopted in reported case series. Aim of this study is to clarify the value of surgical therapy for type II-IV HH. The investigators report on patients who were followed up after surgery at various time points over the course of 30 years.

NCT ID: NCT01605851 Completed - Clinical trials for Closure; Foramen Ovale

GORE® Septal Occluder European Union Clinical Evaluation

Start date: May 2012
Phase: N/A
Study type: Interventional

The primary objective of this study is to evaluate clinical success and performance of the GORE® Septal Occluder when used for percutaneous, transcatheter closure of Patent Foramen Ovale (PFO).

NCT ID: NCT01605227 Completed - Prostate Cancer Clinical Trials

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

COMET-1
Start date: July 2012
Phase: Phase 3
Study type: Interventional

This study will evaluate the effect of cabozantinib compared to prednisone on overall survival in men with previously treated metastatic castration-resistant prostate cancer with bone-dominant disease who have experienced disease progression on docetaxel-containing chemotherapy and abiraterone or MDV3100.

NCT ID: NCT01604811 Completed - Clinical trials for Benign Prostatic Hyperplasia (BPH)

Exploratory Study of L.S.E.S.r. (LipidoSterolic Extract of Serenoa Repens)(PERMIXON® 160 mg Hard Capsule) Versus Tamsulosine LP Activity on Inflammation Biomarkers in Urinary Symptoms Related to BPH (Benign Prostatic Hyperplasia)

PERMIN
Start date: June 2012
Phase: Phase 4
Study type: Interventional

Inflammation is reported as one of the most recent hypotheses to explain BPH. Recent published works pointed out that urine and serum markers could be used for detection of prostatic inflammation. The aim of the study is to assess the activity on inflammation biomarkers (serum and urine inflammation markers) of Permixon® 160 mg hard capsule and Tamsulosine Arrow LP in the treatment of urinary symptoms related to BPH. The potential links between serum and urinary markers of inflammation and BPH clinical symptoms at baseline and on treatment will be explored.